9 results about "Relaxin" patented technology

The present disclosure provides relaxin-2 fusion protein analogs having an enhanced in vivo half-life and methods of making the same. Also disclosed herein are methods of treating relaxin-2 related conditions or diseases using the relaxin-2 fusion protein analogs described herein.

The invention relates to a traditional Chinese medicine composition for treating ischemic heart failure and a preparation method thereof, and belongs to the field of traditional Chinese medicine pharmacy, and the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 5-15 parts of cassia twig, 5-15 parts of bighead atractylodes rhizome, 5-15 parts of poria cocos, 6-12 parts of rhizoma zingiberis, 5-15 parts of acanthopanax, 10-30 parts of fructus polygoni orientalis, 3-9 parts of verbena, 6-12 parts of dogwood and 3-9 parts of honey-fried licorice root. The composition can remarkably reduce the level of N-terminal proB-type natriuretic peptide, remarkably improve pathological changes of heart tissues of model rats, regulate and control the heart functions of the model rats, improve the systolic function of the heart, relieve expression of inflammatory factors such as interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha of the rats and improve the anti-inflammatory effect of the rats. The action mechanism of the compound relates to a plurality of pathways such as extracellular matrix receptor interaction, a chemotactic factor signal pathway, a relaxin signal pathway, a cyclic adenosine monophosphate signal pathway, a nuclear factor-kB signal pathway, fatty acid metabolism and a Toll-like receptor signal pathway, and the compound is an effective medicament for treating ischemic heart failure.

The invention relates to an application technology in the field of drug research, in particular to an anti-tumor cell relaxin alkaloid compound as well as preparation and application thereof. The alkaloid compounds are compounds 1-4 as shown in a formula I, the molecular formula of the compound 1 is C29H35NO4, and the structural formula of the compound 1 is 1 in the formula I; the molecular formula of the compound 2 is C29H35NO4, and the structural formula is 2 in the formula I; the molecular formula of the compound 3 is C29H35NO5, and the structural formula is 3 in the formula I; the molecular formula of the compound 4 is C29H39NO5, and the structural formula is 4 in the formula I. Compared with a traditional chemical synthesis route, the method adopts a microbial fermentation technology to realize preparation of the target compound, not only avoids complex organic synthesis steps and use of expensive and toxic reagents, but also has the characteristics of simple and convenient process flow, mild culture conditions, shorter production period, lower raw material cost and the like, is suitable for large-scale production, and has a wide application prospect. The invention provides an economic and sustainable preparation way for subsequent drug development, and shows a good application prospect in the field of antitumor drug research and development.

The present disclosure provides relaxin-2 fusion protein analogs with enhanced in vivo half-lives and methods for making same. Also disclosed herein are methods of treating relaxin-2-associated disorders or diseases using the relaxin-2 fusion protein analogs described herein.

The present invention relates to heterodimeric relaxin fusion polypeptides, in particular to heterodimeric relaxin 2 fusion polypeptides and uses thereof. Accordingly, the present invention provides relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same as well as uses thereof including therapeutic methods. The polypeptides and compositions of the present invention are particularly useful for the treatment of cardiovascular diseases, for example for the treatment of heart failure.

Relaxin (RLN) analogs are disclosed including modifications that increase half-life when compared to native, human RLN, that maintain selectivity to the RXFP1 receptor and that provide in vitro and in vivo stability for improved druggability properties and less immunogenicity. Pharmaceutical compositions also are disclosed that include one or more of the RLN analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the RLN analogs also are disclosed, especially for treating cardiovascular, pulmonary and / or renal conditions, diseases or disorders.

The present disclosure provides relaxin-2 fusion protein analogs with enhanced in vivo half-lives and methods for making same. Also disclosed herein are methods of treating relaxin-2-associated disorders or diseases using the relaxin-2 fusion protein analogs described herein.

The present application relates to a kind of traditional Chinese medicine composition for treating ischemic heart failure and preparation method thereof, belong to the field of traditional Chinese medicine pharmacy, the traditional Chinese medicine composition includes: cassia 5-15 parts, white atractylodes 5-15 parts, poria 5-15 parts, dried ginger 6-12 parts, acanthopanax 5-15 parts, water red flower seed 10-30 parts, verbena 3-9 parts, dogwood 6-12 parts, fried licorice 3-9 parts.The composition can significantly reduce N-terminal B-type natriuretic peptide level, significantly improve model rat heart tissue pathological changes, regulate the heart function of model rat, improve the systolic function of heart, and can reduce the expression of rat interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha and other inflammatory factors, involve extracellular matrix receptor interaction, chemotactic factor signal pathway, relaxin signal pathway, cyclic adenosine monophosphate signal pathway, nuclear factor-kappa B signal pathway and multiple pathways, and is effective drug for treating ischemic heart failure.

Provided herein are small molecule modulators of RXFP1, and methods of making and use thereof. These compounds are pharmacological mimetics of relaxin H2 signaling and are capable of activating RXFP1. This activation triggers intracellular signaling pathways that mediate physiological functions in many tissues, including the reproductive, cardiovascular, renal, hepatic, and connective tissues. As such, these compounds are useful in the treatment of a variety of indications, including heart failure and other RXFP1 related diseases in patients in need thereof.